medigraphic.com
ISSN 0188-9796 (Print)

2008, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2008; 16 (3)

Therapeutic aspects of statins and their multiorgan effects

Fernández-Aguilar O, García-Ulloa AC, Torres-Viloria A, Zacarías-Castillo R

Language: Spanish
References: 24
Page: 120-127
PDF size: 112.68 Kb.


ABSTRACT

Statins are the treatment of hypercholesterolaemia. Multiple studies with statins at different dosis have shown reduction in c-LDL, cardiovascular events and mortality. The cerebrovascular disease has been related with atherosclerosis. Multiple studies have shown that the use of statins diminishes 19-32% of the relative risk for CVD and even 60% when the treatment is initiated during an acute coronary syndrome. Statins also inhibit the synthesis of isoprenoids, which affect the osteoclastic activity. This increases the expression of multiple proteins necessary in the osteoblastic differentiation, bone mineralization and fostering lubrication of such tissues. In kidney, statins have an antisclerotic effect. Their utility has been prooven in prostatic, colon, rectum lung and breast cancer, where the levels of hormones derived from cholesterol have an important role. Another effect of statins is in antiretroviral therapy, avoiding the HIV virus replication in the cells and blocking its cellular internalization on high cholesterol zones. For this reason, the pleiotropic effects of statins should also be considered for their prevention and therapeutic use in multiple pathologies.


REFERENCES

  1. Steinberg D. The discovery of the statins and the end of the controversy. J Lipid Res 2006; 47: 1339-1351.

  2. Bouknight P, Mackler L, Heffington M. Best alternatives to statins for treating hyperlipidemia. Am Fam Physician 2007; 76: 1027-9.

  3. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781.

  4. Lamonte MP. Evaluation and management of transient ischemic attacks. Clin Geriatr Med 2007; 23: 401-12.

  5. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: The cholesterol and recurrent events (CARE) study. Circulation 1999; 99: 216-23.

  6. The long term intervention with pravastatin in ischemic disease (LIPID) Study group. Prevention of cardiovascular events and deith with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

  7. White HD, Simes J, Anderson NE, Graeme JH et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-326.

  8. Water DD, Schwartz GG, Olson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or no-Q wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL). Circulation 2002; 106: 1690-1695.

  9. Castilla-Guerra L, Balbuena-García M, Fernández-Moreno MC. Estatinas en la prevención secundaria del AIT en la comunidad. Aten Primaria 2007; 39: 373-6.

  10. Sever PS, Dahlöf B, Poulter NR, Wederls J et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower than average cholesterol concentrations, in the angle svandinavian cardia outcomes trial- lipid lowering arm (ASCOTT-LLA): a multicentre randomized controlled trial. Lancet 2003: 361: 1149-1158.

  11. Fey RE. Statins for prevention of stroke. Lancet 1998; 325: 144-145.

  12. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-1973.

  13. Amarenco P, Bougasslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.

  14. Hennekens C, Hollar D, Eidelman RS et al. Update for primary care providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Med Gen Med 2006; 8: 54.

  15. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007; 40: 1581-7.

  16. Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006; 12: 85-101.

  17. Pritchett JW. Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin Orthop Relat Res 2007; 456: 233-7.

  18. Rizzo M, Rini GB. Statins, fracture risk, and bone remodeling. Am J Med Sci 2006; 332: 55-60.

  19. Cooper ME, Jandeleit-Dahm KA. Lipids and diabetic renal disease. Curr Diab Rep 2005; 56: 445-8.

  20. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-42.

  21. Boursi B, Arber N. Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des 2007; 13: 2274-82.

  22. del Real G, Jiménez-Baranda S, Mira E, Lacalle RA, Lucas P, Gómez-Moutón C, Alegret M, Peña JM, Rodríguez-Zapata M, Alvarez-Mon M, Martínez-AC, Mañes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200: 541-7.

  23. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001; 15: 1503-8.

  24. Zarowitz BJ. Are statins safe? Geriatr Nurs 2007; 28: 212-7.




2020     |     www.medigraphic.com